Xiao-Mao Guo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6559206/publications.pdf

Version: 2024-02-01

64 1,112 19 30 g-index

64 64 64 1947

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: A systematic review and meta-analysis. Radiotherapy and Oncology, 2015, 114, 289-295.	0.3	109
2	Targeting deubiquitinase USP28 for cancer therapy. Cell Death and Disease, 2018, 9, 186.	2.7	81
3	The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy. Acta Pharmacologica Sinica, 2017, 38, 513-523.	2.8	63
4	HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 45186-45198.	0.8	58
5	Is it possible for knowledge-based planning to improve intensity modulated radiation therapy plan quality for planners with different planning experiences in left-sided breast cancer patients?. Radiation Oncology, 2017, 12, 85.	1.2	49
6	Stanniocalicin 2 Suppresses Breast Cancer Cell Migration and Invasion via the PKC/Claudin-1-Mediated Signaling. PLoS ONE, 2015, 10, e0122179.	1.1	42
7	Phyllodes tumors of the breast: diagnosis, treatment and prognostic factors related to recurrence. Journal of Thoracic Disease, 2016, 8, 3361-3368.	0.6	39
8	CDK4/6 inhibitors: a novel strategy for tumor radiosensitization. Journal of Experimental and Clinical Cancer Research, 2020, 39, 188.	3.5	35
9	Radiomics predicts the prognosis of patients with locally advanced breast cancer by reflecting the heterogeneity of tumor cells and the tumor microenvironment. Breast Cancer Research, 2022, 24, 20.	2.2	34
10	Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Molecular Cancer, 2022, 21, 84.	7.9	34
11	Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab. Oncologist, 2015, 20, 605-614.	1.9	33
12	Postoperative chemoradiotherapy versus chemotherapy for RO resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World Journal of Surgical Oncology, 2016, 14, 209.	0.8	31
13	Systematic review and meta-analysis comparing hypofractionated with conventional fraction radiotherapy in treatment of early breast cancer. Surgical Oncology, 2015, 24, 200-211.	0.8	27
14	Prognostic factors in breast phyllodes tumors: a nomogram based on a retrospective cohort study of 404 patients. Cancer Medicine, 2018, 7, 1030-1042.	1.3	27
15	Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells. Oncotarget, 2016, 7, 38380-38391.	0.8	25
16	Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials. Critical Reviews in Oncology/Hematology, 2015, 94, 323-336.	2.0	24
17	Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab. Oncotarget, 2016, 7, 1042-1054.	0.8	23
18	Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis. Breast Cancer, 2016, 23, 732-739.	1.3	22

#	Article	IF	CITATIONS
19	Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells. Medical Science Monitor, 2017, 23, 2674-2683.	0.5	22
20	Association between breast cancer and thyroid cancer: A study based on 13Â978 patients with breast cancer. Cancer Medicine, 2018, 7, 6393-6400.	1.3	21
21	Targeting the Neddylation Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men's Cancer. BioMed Research International, 2014, 2014, 1-8.	0.9	20
22	Diagnostic performance of core needle biopsy in identifying breast phyllodes tumors. Journal of Thoracic Disease, 2016, 8, 3139-3151.	0.6	18
23	Internal Mammary Node Irradiation (IMNI) Improves Survival Outcome for Patients With Clinical Stage II-III Breast Cancer After Preoperative Systemic Therapy. International Journal of Radiation Oncology Biology Physics, 2019, 103, 895-904.	0.4	17
24	Treatment outcome of patients with stages l–II nasopharyngeal carcinoma after late course accelerated hyperfractionation radiotherapy alone. Oral Oncology, 2012, 48, 1058-1063.	0.8	15
25	The efficacy of postoperative radiotherapy in localized primary soft tissue sarcoma treated with conservative surgery. Radiation Oncology, 2016, 11, 25.	1.2	15
26	Dose coverage of axillary level I-III areas during whole breast irradiation with simplified intensity modulated radiation therapy in early stage breast cancer patients. Oncotarget, 2015, 6, 18183-18191.	0.8	15
27	Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma. World Journal of Gastroenterology, 2017, 23, 540.	1.4	14
28	Building radiation-resistant model in triple-negative breast cancer to screen radioresistance-related molecular markers. Annals of Translational Medicine, 2020, 8, 108-108.	0.7	12
29	Targeting CDK7 suppresses super enhancer-linked inflammatory genes and alleviates CAR T cell-induced cytokine release syndrome. Molecular Cancer, 2021, 20, 5.	7.9	12
30	Local recurrence is correlated with decreased overall survival in patients with intermediate highâ€grade localized primary soft tissue sarcoma of extremity and abdominothoracic wall. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e109-e115.	0.7	10
31	Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II–III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy. OncoTargets and Therapy, 2018, Volume 11, 1973-1980.	1.0	10
32	The Impact of Radiotherapy on Reoperation Rates in Patients Undergoing Mastectomy and Breast Reconstruction. Annals of Surgical Oncology, 2019, 26, 961-968.	0.7	10
33	Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis. Journal of Cancer Research and Therapeutics, 2016, 12, 775.	0.3	10
34	Adjuvant breast inversely planned intensity-modulated radiotherapy with simultaneous integrated boost for early stage breast cancer. Strahlentherapie Und Onkologie, 2020, 196, 764-770.	1.0	9
35	Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion. Cancer Medicine, 2021, 10, 7203-7212.	1.3	9
36	Intensity modulated radiotherapy with fixed collimator jaws for locoregional left-sided breast cancer irradiation. Oncotarget, 2017, 8, 33276-33284.	0.8	8

#	Article	IF	Citations
37	The survival benefit of radiotherapy in localized primary adult rhabdomyosarcoma. Asia-Pacific Journal of Clinical Oncology, 2020, 16, 266-272.	0.7	7
38	Biological subtype predicts locoregional recurrence after postmastectomy radiotherapy in Chinese breast cancer patients. Cancer Medicine, 2020, 9, 2427-2434.	1.3	7
39	Internal mammary node irradiation improves 8-year survival in breast cancer patients: results from a retrospective cohort study in real-world setting. Breast Cancer, 2020, 27, 252-260.	1.3	6
40	Postoperative radiotherapy improves overall survival in patients with primary squamous cell carcinoma of the breast. Asia-Pacific Journal of Clinical Oncology, 2020, 17, 454-461.	0.7	6
41	Impact of clinical-pathological factors on locoregional recurrence in mastectomy patients with T1-2N1 breast cancer: who can omit adjuvant radiotherapy?. Breast Cancer Research and Treatment, 2021, 190, 277-286.	1.1	6
42	Multibeam inverse intensity-modulated radiotherapy (IMRT) for whole breast irradiation: a single center experience in China. Oncotarget, 2015, 6, 35063-35072.	0.8	6
43	Isolated locoregional recurrence patterns of breast cancer after mastectomy and adjuvant systemic therapies in the contemporary era. Oncotarget, 2015, 6, 36860-36869.	0.8	6
44	Is internal mammary nodes irradiation as a part of breast cancer postoperative radiotherapy necessary?. Journal of Thoracic Disease, 2016, 8, 3427-3430.	0.6	5
45	Highlights on molecular targets for radiosensitization of breast cancer cells: Current research status and prospects. Cancer Medicine, 2018, 7, 3110-3117.	1.3	5
46	Does the protocol-required uniform margin around the CTV adequately account for setup inaccuracies in whole breast irradiation?. Radiation Oncology, 2021, 16, 143.	1.2	5
47	Complete response after chemotherapy and radiotherapy of a tonsillar histiocytic sarcoma with regional lymph node involvement: a case report and review of the literature. International Journal of Clinical and Experimental Medicine, 2015, 8, 16808-12.	1.3	5
48	Outcomes Following Salvage Radiation and Systemic Therapy for Isolated Locoregional Recurrence of Breast Cancer after Mastectomy: Impact of Constructed Biologic Subtype. Journal of Oncology, 2018, 2018, 1-10.	0.6	4
49	<p>Single institution experience of split course radiotherapy in patients with desmoid tumors</p> . OncoTargets and Therapy, 2019, Volume 12, 1741-1748.	1.0	4
50	The Expressions and Mechanisms of Sarcomeric Proteins in Cancers. Disease Markers, 2020, 2020, 1-16.	0.6	4
51	Association between breast cancer cell migration and radiosensitivity in�vitro. Oncology Letters, 2019, 18, 6877-6884.	0.8	4
52	Carbon Ion Radiotherapy Evokes a Metabolic Reprogramming and Individualized Response in Prostate Cancer. Frontiers in Public Health, 2021, 9, 777160.	1.3	4
53	The influence of anatomic location on outcomes in patients with localized primary soft tissue sarcoma. Japanese Journal of Clinical Oncology, 2018, 48, 799-805.	0.6	3
54	Symptoms Related to Brachial Plexus Neuropathy After Supraclavicular Irradiation and Boost in Breast Cancer. Practical Radiation Oncology, 2021, , .	1.1	3

#	Article	IF	CITATIONS
55	Management experiences of primary angiosarcoma of breast: a retrospective study from single institute in the People's Republic of China. OncoTargets and Therapy, 2015, 8, 3237.	1.0	2
56	Elevated Risk of Radiation Therapy–Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 275-284.	0.4	2
57	Clinicopathological Characteristics of Breast Ductal Carcinoma In Situ: An Analysis of Chinese Population of 617 Patients. Journal of Oncology, 2021, 2021, 1-6.	0.6	2
58	Outcomes in Patients with pT3N0M0 Breast Cancer with and without Postmastectomy Radiotherapy. Cancer Management and Research, 2021, Volume 13, 3889-3899.	0.9	2
59	Intraoperative radiotherapy for the treatment of thyroid cancer: a pilot study. Oncotarget, 2017, 8, 29355-29360.	0.8	2
60	Prospective evaluation of skin toxicities in patients receiving post-mastectomy irradiation of chest wall, supra/infraclavicular and internal mammary nodes delivered by conventional versus intensity-modulated radiotherapy technique. Oncotarget, 2017, 8, 80012-80019.	0.8	2
61	Prognostic value of metabolic signature on 18F-FDG uptake in breast cancer patients after radiotherapy. Molecular Therapy - Oncolytics, 2021, 23, 412-419.	2.0	2
62	Radiation-induced skin injury: pathogenesis, treatment, and management. Aging, 2020, 12, 23379-23393.	1.4	2
63	Molecular subtypes predict second breast events of ductal carcinoma in situ after breastâ€conserving surgery. Cancer Medicine, 0, , .	1.3	2
64	In Regard to Brown et al. International Journal of Radiation Oncology Biology Physics, 2015, 93, 722-723.	0.4	1